Kiora Pharmaceuticals, Inc.
KPRX Healthcare Biotechnology
Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million. In the quarter to June 2026, EPS grew 37.0% and free cash flow grew 50.1%, each against the same quarter a year earlier.
Follow KPRX
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Gross Profit |
— | — | — | — |
+8 more quarters Free account |
R&D Expenses |
2.08 | 2.12 | 2.93 | 2.73 | |
SG&A Expenses |
1.38 | 1.61 | 1.46 | 1.44 | |
Operating Income |
(2.21) | (2.51) | (7.31) | (0.79) | |
Non-operating Income/Expense |
0.13 | 0.09 | 0.14 | 0.18 | |
| (2.08) | (2.42) | (7.17) | (0.62) | ||
Income Tax Provision |
— | — | (0.65) | (0.64) | |
Income after Tax |
(2.08) | (2.42) | (6.52) | 0.03 | |
Net Income Common |
(2.08) | (2.42) | (6.52) | 0.03 | |
EPS (Basic) |
(0.34) | (0.58) | (1.56) | 0.01 | |
EPS (Diluted) |
(0.34) | (0.58) | (1.60) | 0.01 | |
Shares (Basic, Weighted) |
6.18 | 4.18 | 4.17 | 4.23 | |
Shares (Diluted, Weighted) |
6.18 | 4.18 | 4.10 | 4.36 | |
EBIT Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBT margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
EBITDA |
(2.20) | (2.50) | (7.30) | (0.78) | |
EBIT |
(2.21) | (2.51) | (7.31) | (0.79) | |
Income from Continuous Operations |
(2.08) | (2.42) | (6.52) | 0.03 | |
Consolidated Net Income/Loss |
(2.08) | (2.42) | (6.52) | 0.03 | |
EPS (Basic, from Continuous Ops) |
(0.34) | (0.58) | (1.55) | 0.01 | |
EPS (Diluted, from Cont. Ops) |
(0.34) | (0.58) | (1.59) | 0.01 | |
EPS (Basic, Consolidated) |
(0.34) | (0.58) | (1.55) | 0.01 | |
EPS (Diluted, Consolidated) |
(0.34) | (0.58) | (1.59) | 0.01 | |
Shares (Diluted, Average) |
6.18 | 4.18 | 4.07 | 4.36 | |
EBITDA Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating Cash Flow Margin |
0.00% | 0.00% | 0.00% | 0.00% |